These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Protein kinase Cdelta activates RelA/p65 and nuclear factor-kappaB signaling in response to tumor necrosis factor-alpha. Lu ZG; Liu H; Yamaguchi T; Miki Y; Yoshida K Cancer Res; 2009 Jul; 69(14):5927-35. PubMed ID: 19549902 [TBL] [Abstract][Full Text] [Related]
23. Bcl-3-regulated transcription from major immediate-early promoter of human cytomegalovirus in monocyte-derived macrophages. Khan KA; Coaquette A; Davrinche C; Herbein G J Immunol; 2009 Jun; 182(12):7784-94. PubMed ID: 19494302 [TBL] [Abstract][Full Text] [Related]
24. Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism. Gupta V; Yeo G; Kawakubo H; Rangnekar V; Ramaswamy P; Hayashida T; MacLaughlin DT; Donahoe PK; Maheswaran S Cancer Res; 2007 Mar; 67(6):2747-56. PubMed ID: 17363596 [TBL] [Abstract][Full Text] [Related]
25. Roxithromycin suppresses involucrin expression by modulation of activator protein-1 and nuclear factor-kappaB activities of keratinocytes. Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Iizuka H J Dermatol Sci; 2005 Sep; 39(3):175-82. PubMed ID: 16140218 [TBL] [Abstract][Full Text] [Related]
26. Lipopolysaccharide from Salmonella enterica activates NF-kappaB through both classical and alternative pathways in primary B Lymphocytes. Souvannavong V; Saidji N; Chaby R Infect Immun; 2007 Oct; 75(10):4998-5003. PubMed ID: 17698569 [TBL] [Abstract][Full Text] [Related]
27. Glucocorticoid receptor functions as a potent suppressor of mouse skin carcinogenesis. Budunova IV; Kowalczyk D; Pérez P; Yao YJ; Jorcano JL; Slaga TJ Oncogene; 2003 May; 22(21):3279-87. PubMed ID: 12761498 [TBL] [Abstract][Full Text] [Related]
28. Reduced nuclear translocation of nuclear factor (NF)-kappaB p65 in the footpad epidermis of dogs infected with distemper virus. Friess M; Engelhardt P; Dobbelaere D; Zurbriggen A; Gröne A J Comp Pathol; 2005 Jan; 132(1):82-9. PubMed ID: 15629482 [TBL] [Abstract][Full Text] [Related]
29. Differential requirement of IKK2 for CYLD-dependent representation of thymic and peripheral T-cell populations. Tsagaratou A; Grammenoudi S; Mosialos G Eur J Immunol; 2011 Oct; 41(10):3054-62. PubMed ID: 21728169 [TBL] [Abstract][Full Text] [Related]
30. Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. Zhang J; Stirling B; Temmerman ST; Ma CA; Fuss IJ; Derry JM; Jain A J Clin Invest; 2006 Nov; 116(11):3042-9. PubMed ID: 17053834 [TBL] [Abstract][Full Text] [Related]
31. The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. Regamey A; Hohl D; Liu JW; Roger T; Kogerman P; Toftgard R; Huber M J Exp Med; 2003 Dec; 198(12):1959-64. PubMed ID: 14676304 [TBL] [Abstract][Full Text] [Related]
32. Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia. Martín-Oliva D; O'Valle F; Muñoz-Gámez JA; Valenzuela MT; Nuñez MI; Aguilar M; Ruiz de Almodóvar JM; Garcia del Moral R; Oliver FJ Oncogene; 2004 Jul; 23(31):5275-83. PubMed ID: 15077172 [TBL] [Abstract][Full Text] [Related]
33. The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-kappaB signaling pathways. Lock FE; Underhill-Day N; Dunwell T; Matallanas D; Cooper W; Hesson L; Recino A; Ward A; Pavlova T; Zabarovsky E; Grant MM; Maher ER; Chalmers AD; Kolch W; Latif F Oncogene; 2010 Jul; 29(30):4307-16. PubMed ID: 20514026 [TBL] [Abstract][Full Text] [Related]
34. Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity. Almeida S; Maillard C; Itin P; Hohl D; Huber M J Invest Dermatol; 2008 Mar; 128(3):587-93. PubMed ID: 17851586 [TBL] [Abstract][Full Text] [Related]
35. Downregulation of cylindromatosis gene, CYLD, confers a growth advantage on malignant melanoma cells while negatively regulating their migration activity. Ishikawa Y; Tsunoda K; Shibazaki M; Takahashi K; Akasaka T; Masuda T; Maesawa C Int J Oncol; 2012 Jul; 41(1):53-60. PubMed ID: 22469839 [TBL] [Abstract][Full Text] [Related]